研究目的比较在近期有急性复发的多发性硬化(MS)患者经静脉注射或口服等量的大剂量甲强龙的疗效、耐受性和安全性。方法选择最近2周内有急性临床复发且脑MRI至少有一个增强病灶的患者40例,将患者随机分为两组,每组各20例,一组给予口服甲强龙1g/d治疗,另一组给予静脉注射甲强龙1g/d治疗,均连续治疗5d。在基线期、第1周和第4周采用扩展的功能缺损状况量表评分 Study Objectives To compare the efficacy, tolerability and safety of high-dose methylprednisolone by intravenous or oral administration in patients with multiple-sclerosis (MS) with acute relapse in the near future. Methods Forty patients with acute clinical relapse and at least one enhanced lesion in brain MRI in the last 2 weeks were randomly divided into two groups with 20 cases in each group. One group was treated with oral methylprednisolone 1 g / d, and the other group was treated with 1 g / A group given intravenous methylprednisolone 1g / d treatment, were treated for 5d. At baseline, week 1 and week 4, an extended scale of functional impairment scale was used